You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 30, 2025

CLINICAL TRIALS PROFILE FOR LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Lactated Ringer's And Dextrose 5% In Plastic Container

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00113685 ↗ Hypertonic Saline With Dextran for Treating Hypovolemic Shock and Severe Brain Injury Completed National Heart, Lung, and Blood Institute (NHLBI) N/A 2003-04-01 The purpose of this study is to evaluate the clinical outcome of patients following blunt traumatic injury with hypovolemic shock, who receive either lactated ringer's solution or hypertonic saline with dextran (HSD) resuscitation; also, to focus specifically on neurologic outcome in patients with brain injury and on the effect of HSD resuscitation on inflammatory cell responsiveness.
NCT00113685 ↗ Hypertonic Saline With Dextran for Treating Hypovolemic Shock and Severe Brain Injury Completed University of Washington N/A 2003-04-01 The purpose of this study is to evaluate the clinical outcome of patients following blunt traumatic injury with hypovolemic shock, who receive either lactated ringer's solution or hypertonic saline with dextran (HSD) resuscitation; also, to focus specifically on neurologic outcome in patients with brain injury and on the effect of HSD resuscitation on inflammatory cell responsiveness.
NCT00181077 ↗ Hypertonic Saline Use in Preeclampsia Completed Johns Hopkins University Phase 1 2003-06-01 To compare hypertonic saline to Lactated Ringer's solution and assess whether one speeds up the process of getting rid of extra body water faster in women with preeclampsia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lactated Ringer's And Dextrose 5% In Plastic Container

Condition Name

Condition Name for Lactated Ringer's And Dextrose 5% In Plastic Container
Intervention Trials
Anesthesia 5
Post-ERCP Acute Pancreatitis 4
Cesarean Section 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lactated Ringer's And Dextrose 5% In Plastic Container
Intervention Trials
Hypotension 16
Pancreatitis 11
Hemorrhage 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lactated Ringer's And Dextrose 5% In Plastic Container

Trials by Country

Trials by Country for Lactated Ringer's And Dextrose 5% In Plastic Container
Location Trials
Egypt 37
United States 33
China 12
Korea, Republic of 5
Brazil 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lactated Ringer's And Dextrose 5% In Plastic Container
Location Trials
Illinois 4
Pennsylvania 3
Connecticut 3
California 3
Minnesota 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lactated Ringer's And Dextrose 5% In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Lactated Ringer's And Dextrose 5% In Plastic Container
Clinical Trial Phase Trials
Phase 4 39
Phase 3 14
Phase 2/Phase 3 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lactated Ringer's And Dextrose 5% In Plastic Container
Clinical Trial Phase Trials
Completed 64
Not yet recruiting 29
Recruiting 26
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lactated Ringer's And Dextrose 5% In Plastic Container

Sponsor Name

Sponsor Name for Lactated Ringer's And Dextrose 5% In Plastic Container
Sponsor Trials
Ain Shams University 9
Cairo University 6
Mansoura University 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lactated Ringer's And Dextrose 5% In Plastic Container
Sponsor Trials
Other 214
Industry 17
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Lactated Ringer's and 5% Dextrose Injection: Clinical Trials, Market Analysis, and Projections

Introduction

Lactated Ringer's and 5% Dextrose Injection is a sterile, nonpyrogenic solution used for fluid and electrolyte replenishment, as well as caloric supply, in patients. This article provides an update on clinical trials, market analysis, and projections for this drug.

Clinical Trials and Safety Profile

Clinical Studies

Clinical studies on Lactated Ringer's and 5% Dextrose Injection have not included sufficient numbers of subjects aged 65 and over to determine if they respond differently from younger subjects. However, other reported clinical experience has not identified significant differences in responses between elderly and younger patients[4][5].

Pediatric Use

The safety and effectiveness of Lactated Ringer's and 5% Dextrose Injection in pediatric patients, especially neonates and low birth weight infants, require close monitoring. These patients are at increased risk of developing hypo- or hyperglycemia, and excessive administration can lead to increased serum osmolality and potential intracerebral hemorrhage[1][3][5].

Geriatric Use

Geriatric patients are at a higher risk of developing electrolyte imbalances due to decreased hepatic, renal, or cardiac function. Dose selection for elderly patients should be cautious, starting at the low end of the dosing range[1][4][5].

Adverse Reactions

Adverse reactions associated with Lactated Ringer's and 5% Dextrose Injection include hypersensitivity and infusion reactions such as angioedema, chest pain, and respiratory distress. Other reactions may include blood pressure changes, tachycardia, and skin manifestations like urticaria and rash[3].

Market Analysis

Market Size and Growth

The global market for 5% Dextrose Injection, which includes Lactated Ringer's and 5% Dextrose Injection, has experienced significant growth. The market is anticipated to continue its expansion from 2023 to 2031, driven by increasing demand for fluid and electrolyte replenishment solutions in various medical settings[2].

Market Segmentation

The market is segmented based on type (250 mL, 500 mL, 1000 mL) and application (First-Aid Treatment, Sports, Trophotherapy, and others). Geographically, the market is divided into North America, Europe, Asia-Pacific, South America, and the Middle-East and Africa[2].

Market Dynamics

The market dynamics are influenced by drivers such as the increasing need for fluid and electrolyte replenishment in hospitals and clinics, and restraints such as the risk of adverse reactions and the need for cautious administration in certain patient populations. Opportunities include the growing demand in emerging markets, while challenges include the competition from other intravenous solutions and the regulatory environment[2].

Projections and Future Outlook

Market Expansion

The 5% Dextrose Injection Market is projected to exhibit robust growth rates throughout the forecast period from 2023 to 2031. This growth is driven by the increasing use of intravenous solutions in various medical applications and the expanding healthcare infrastructure in developing regions[2].

Technological Advancements

Advancements in packaging technology, such as the use of VIAFLEX plastic containers, have improved the safety and convenience of administering Lactated Ringer's and 5% Dextrose Injection. These containers have been tested for safety and have shown no significant leaching of chemical components into the solution[3][5].

Regulatory Considerations

Regulatory bodies continue to monitor the safety and efficacy of Lactated Ringer's and 5% Dextrose Injection. Manufacturers must adhere to strict guidelines to ensure the product meets safety standards, including the absence of antimicrobial agents and the use of non-toxic plastic materials[3][5].

Key Considerations for Administration

Dosage and Administration

The dosage of Lactated Ringer's and 5% Dextrose Injection is dependent on the patient's age, weight, and clinical condition. It must be administered intravenously using sterile equipment, and the solution should be inspected visually for particulate matter and discoloration before administration[1][3][5].

Precautions

The solution should be used with caution in patients receiving corticosteroids or corticotropin, and in those with overt or subclinical diabetes mellitus. Excess administration can result in metabolic alkalosis, and patients with known allergy to corn or corn products should avoid this solution[1][3][5].

Key Takeaways

  • Clinical Trials: Limited clinical trials in elderly and pediatric populations, with a need for cautious administration.
  • Market Analysis: Significant growth projected from 2023 to 2031, driven by increasing medical needs.
  • Market Segmentation: Segmented by type, application, and geographical region.
  • Future Outlook: Robust growth expected, driven by technological advancements and expanding healthcare infrastructure.
  • Regulatory Considerations: Strict adherence to safety standards and guidelines.

FAQs

Q: What are the primary components of Lactated Ringer's and 5% Dextrose Injection?

A: The solution contains 5 g Dextrose Hydrous, 600 mg Sodium Chloride, 310 mg Sodium Lactate, 30 mg Potassium Chloride, and 20 mg Calcium Chloride per 100 mL[3].

Q: What are the contraindications for Lactated Ringer's and 5% Dextrose Injection?

A: Contraindications include hypersensitivity to any ingredient, concomitant administration of ceftriaxone in newborns, and known allergy to corn or corn products[5].

Q: How should the solution be administered?

A: The solution should be administered intravenously using sterile equipment, and the dosage is dependent on the patient's age, weight, and clinical condition[1][3][5].

Q: What are the potential adverse reactions?

A: Adverse reactions include hypersensitivity and infusion reactions, blood pressure changes, tachycardia, and skin manifestations like urticaria and rash[3].

Q: What is the market outlook for Lactated Ringer's and 5% Dextrose Injection?

A: The market is projected to exhibit robust growth from 2023 to 2031, driven by increasing medical needs and technological advancements[2].

Sources

  1. RxList: Lactated Ringers in 5% Dextrose - RxList
  2. Market Research Intellect: Global 5% Dextrose Injection Market Size, Scope And Forecast Report
  3. FDA: Lactated Ringer's and 5% Dextrose Injection, USP
  4. Drugs.com: Dextrose in Ringer's: Package Insert / Prescribing Info
  5. Baxter: Lactated Ringer's and 5% Dextrose Injection, USP In Viaflex Plastic Container

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.